Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NCNA
stocks logo

NCNA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
--
--
-2.600
-99.41%
Estimates Revision
The market is revising No Change the revenue expectations for NuCana plc (NCNA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 54.36%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+54.36%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for NuCana PLC (NCNA.O) is -85.19, compared to its 5-year average forward P/E of -10.37. For a more detailed relative valuation and DCF analysis to assess NuCana PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.37
Current PE
-85.19
Overvalued PE
19.27
Undervalued PE
-40.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.54
Undervalued EV/EBITDA
-1.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.26
Current PS
0.00
Overvalued PS
12.31
Undervalued PS
-7.80
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NCNA News & Events

Events Timeline

(ET)
2025-11-05
08:14:30
NuCana Secures Composition-of-Matter Patent for NUC-7738 in China
select
2025-10-19 (ET)
2025-10-19
17:07:00
NuCana showcases NUC-7738 and PD-1 inhibitors data at ESMO 2025
select
2025-10-14 (ET)
2025-10-14
08:10:33
NuCana Reveals New Data Publication for NUC-3373
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
09-12Benzinga
Major Stocks Including IBEX, Tesla, IonQ, and Warner Bros. Discovery Rise on Friday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones index dropping over 100 points on Friday, while several companies, including IBEX Limited, saw significant gains after reporting strong financial results.

  • IBEX Limited's Financial Success: IBEX Limited's shares surged 33.7% to $40.74 after reporting quarterly earnings of 87 cents per share, exceeding analyst expectations, and providing optimistic sales guidance for FY26.

[object Object]
Preview
7.0
09-05SeekingAlpha
NuCana Gets Compliance Notice from Nasdaq

  • Compliance Notification: NuCana has received formal notification from Nasdaq confirming compliance with all continued listing criteria, including the $1.00 minimum bid price requirement.

  • Stock Performance: Following the announcement, NuCana's stock (NCNA) rose by 2.44% in premarket trading, reaching a price of $2.93.

[object Object]
Preview
9.0
09-03Newsfilter
NuCana to Showcase Findings on NUC-7738's Combined Effect with PD-1 Inhibitors at ESMO Congress 2025

  • NuCana's Presentation at ESMO Congress 2025: NuCana plc will present research on the synergy between NUC-7738 and PD-1 inhibition in renal cell cancer at the ESMO Congress 2025, scheduled for October 17-21 in Berlin, with the presentation set for October 19.

  • About NuCana's Drug Development: NuCana is focused on enhancing cancer treatment through its ProTide technology, with ongoing clinical studies for its drug candidates NUC-7738 and NUC-3373, aimed at improving efficacy and safety in cancer therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NuCana PLC (NCNA) stock price today?

The current price of NCNA is 4.43 USD — it has increased 4.48 % in the last trading day.

arrow icon

What is NuCana PLC (NCNA)'s business?

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

arrow icon

What is the price predicton of NCNA Stock?

Wall Street analysts forecast NCNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NCNA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NuCana PLC (NCNA)'s revenue for the last quarter?

NuCana PLC revenue for the last quarter amounts to -3.57M USD, decreased -29.90 % YoY.

arrow icon

What is NuCana PLC (NCNA)'s earnings per share (EPS) for the last quarter?

NuCana PLC. EPS for the last quarter amounts to 1342000.00 USD, decreased -129.27 % YoY.

arrow icon

What changes have occurred in the market's expectations for NuCana PLC (NCNA)'s fundamentals?

The market is revising No Change the revenue expectations for NuCana plc (NCNA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 54.36%.
arrow icon

How many employees does NuCana PLC (NCNA). have?

NuCana PLC (NCNA) has 20 emplpoyees as of December 05 2025.

arrow icon

What is NuCana PLC (NCNA) market cap?

Today NCNA has the market capitalization of 18.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free